Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Dec 2

PMID 39619133

Authors

Xiang Han

Yunhong You

Xiuhui Guo

Youxin Ji

Keke Nie

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the efficiency and safety of afatinib in combination with bevacizumab in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) G719X, S768I, and L861Q mutations.

Patients And Methods: We retrospective studied treatment naïve patients with local advanced or metastatic non-small cell lung cancer harboring EGFR G719X, S768I, and L861Q mutations from January 2017 to August 2021. EGFR tyrosine kinase inhibitors (TKIs) were the first-line treatment in all patients. The demographic, clinical data and treatment results were collected and analyzed.

Results: A total of 12 Chinese patients were studied. There were seven EGFR G719X mutations, three of the seven patients with single mutation and the others with compound mutations. Four patients had EGFR S768I mutations and one of them with single mutation. Four patients had EGFR L861Q/P mutations and one of them with compound mutations. The overall response rate of the EGFR TKIs treatment was 58.33% (7/12). The median progression-free survival (PFS) was 11.0 months, and median overall survival (OS) was 35.40 months. Two of five (40%) patients had required EGFR T790M mutations after TKIs were resistant. The side effects were mild to moderate hand-foot-syndrome, hypertension, and proteinuria.

Conclusion: Afatinib in combination with bevacizumab are effective and safe in the management of patients with NSCLC harboring EGFR G719X, S768I, L861Q/P single or compound mutations.

References

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Sholl L, Aisner D, Varella-Garcia M, Berry L, Dias-Santagata D, Wistuba I . Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015; 10(5):768-777. PMC: 4410843. DOI: 10.1097/JTO.0000000000000516. View

Qin Y, Jian H, Tong X, Wu X, Wang F, Shao Y . Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol Oncol. 2020; 14(8):1695-1704. PMC: 7400778. DOI: 10.1002/1878-0261.12710. View

Yasuda H, Kobayashi S, Costa D . EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2011; 13(1):e23-31. DOI: 10.1016/S1470-2045(11)70129-2. View

Alizade-Harakiyan M, Ghasemi Jangjoo A, Jafari-Koshki T, Fatemi A, Mesbahi A . Radiobiological modeling of acute esophagitis after radiation therapy of head, neck, and thorax tumors: The influence of chemo-radiation. J Cancer Res Ther. 2022; 18(6):1706-1715. DOI: 10.4103/jcrt.JCRT_271_20. View

Zhu X, Bai Q, Lu Y, Qi P, Ding J, Wang J . Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review. Target Oncol. 2016; 12(1):81-88. DOI: 10.1007/s11523-016-0455-4. View

Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S . Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019; 20(5):625-635. DOI: 10.1016/S1470-2045(19)30035-X. View

Kris M, Johnson B, Berry L, Kwiatkowski D, Iafrate A, Wistuba I . Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311(19):1998-2006. PMC: 4163053. DOI: 10.1001/jama.2014.3741. View

Yatabe Y, Kerr K, Utomo A, Rajadurai P, Tran V, Du X . EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2014; 10(3):438-45. PMC: 4342317. DOI: 10.1097/JTO.0000000000000422. View

10.

Wu S, Chang Y, Hsu Y, Wu J, Yang C, Yu C . Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist. 2008; 13(12):1276-84. DOI: 10.1634/theoncologist.2008-0093. View

11.

Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S . Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014; 9(2):189-94. PMC: 4132025. DOI: 10.1097/JTO.0000000000000048. View

12.

Murray S, Dahabreh I, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P . Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol. 2008; 3(8):832-9. DOI: 10.1097/JTO.0b013e31818071f3. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C . EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res. 2015; 21(23):5305-13. DOI: 10.1158/1078-0432.CCR-15-1046. View

15.

Shi J, Yang H, Jiang T, Li X, Zhao C, Zhang L . Uncommon mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. Chin J Cancer Res. 2018; 29(6):543-552. PMC: 5775013. DOI: 10.21147/j.issn.1000-9604.2017.06.09. View

16.

Arrieta O, Cardona A, Corrales L, Campos-Parra A, Sanchez-Reyes R, Amieva-Rivera E . The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 2015; 87(2):169-75. DOI: 10.1016/j.lungcan.2014.12.009. View

17.

Lohinai Z, Hoda M, Fabian K, Ostoros G, Raso E, Barbai T . Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. J Thorac Oncol. 2015; 10(5):738-746. DOI: 10.1097/JTO.0000000000000492. View

18.

Keam B, Kim D, Park J, Lee J, Kim T, Lee S . Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol. 2013; 19(4):594-600. DOI: 10.1007/s10147-013-0602-1. View

19.

Wu T, Hsiue E, Lee J, Lin C, Yang J . New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Rev Respir Med. 2016; 11(1):51-55. DOI: 10.1080/17476348.2017.1267569. View

20.

Kobayashi S, Canepa H, Bailey A, Nakayama S, Yamaguchi N, Goldstein M . Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2012; 8(1):45-51. PMC: 3531043. DOI: 10.1097/JTO.0b013e3182781e35. View